Of the breast cancer cases for whom receptor status data were available, the distribution of ER+ and PR+ but not HER2+ was similar to that reported by the Tuscany Cancer Registry among all the invasive breast cancer cases diagnosed during the period 2004–2005 (Caldarella et al. 2011). This evidence concerns the gene PGR and invasive breast carcinoma.